Our purpose is to investigate the reasons why erythropoiesis remains suppressed in the majority of maintenance dialysis patients. Although a hypoproliferative anemia exists in all patients with chronic renal failure, some improve their anemia, most likely because of increased renal and/or non-renal erythropoietin (Ep) production. We propose to determine if the following factors contribute to continued erythropoietic suppression: 1) inhibitors retained in uremic sera; 2) hypertransfusion or repetitive red cell transfusions; 3) aluminum (Al) suppression of home synthesis; 4) inappropriate Ep production in the absence of all of the above three conditions. Coversely, we plan to determine if erythropoiesis is stimulated by the following factors: 1) Removal of inhibitors by dialysis (if specific erythropoietic inhibitors can be confirmed in vitro); 2) phlebotomy induced hypoxemia; 3) desferrioxamine removal of aluminum from marrow tissue; 4) human Ep-rich plasma (ERP) into very anemic dialysis patients compared with follow-up studies done when hematologically normal after kidney transplantations; and 5) the development of acquired renal cystic disease. If specific inhibitors of erythropoiesis are present in uremic sera as defined in vitro, efforts will undertaken to determine their significance in vivo by quantitative erythropoiesis and serum Ep levels in CAPD patients, hemodialysis patients using a more porous dialyzer membrane and a control group. The erythropoietic effects of hypertransfusion and phlebotomy will be studied to see if the reciprocal changes in Ep production and erythropoiesis, observed in normals, are found in uremia or whether these changes will be blunted or non-existent. If erythropoiesis is suppressed by hypertransfusion as determined by ferrokinetics, marrow morphology will be examined for macrophage-like cells, thought to be the "nurse" cells to erythroid precursors. Al suppression of erythropoiesis will be ascertained by correlating marrow levels of Al, as quantitated by electron probe microanalysis, to serum Al levels, and ferrokinetics. The definitive test as to whether erythropoietic inhibitors exist will be the response in human uremia to infusions of human ERP compared to normal renal function. An indirect assessment of Ep action will be to determine if erythropoiesis and serum Ep levels improve mainly in patients developing acquired renal cystic disease.
NIH ExPorter
NIH ExPorter